United States · FDA National Drug Code directory
Rejuvesol
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 23731-7000_f07bc3c3-29f0-4f71-9696-47a1c2ec5bf2
- Product NDC
- 23731-7000
- Form
- SOLUTION
- Composition / generic term
- Sodium Pyruvate, Inosine, Adenine, Sodium Phosphate, Dibasic, and Sodium Phosphate, Monobasic, Monohydrate
- Labeler
- Citra Labs, LLC
- Marketing category
- NDA
- Marketing start / end (source format)
- 19970226
- Source listing expiry
- 20261231
Source-listed ingredients
- SODIUM PYRUVATE — .55 g/50mL
- INOSINE — 1.34 g/50mL
- ADENINE — .034 g/50mL
- SODIUM PHOSPHATE, DIBASIC — .73 g/50mL
- SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE — .311 g/50mL
These values do not establish equivalence or a dose recommendation.
Packages
- 12 VIAL, SINGLE-USE in 1 CASE (23731-7000-5) / 50 mL in 1 VIAL, SINGLE-USE · 23731-7000-5
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →